Table 2—

Baseline demographics and characteristics and baseline to end point changes in the glycemic control variables of the analysis population

Insulin glargineNPH insulin
Sex
    Men636 (56)652 (56)
    Women506 (44)510 (44)
Age (years)58.0 ± 9.858.4 ± 9.3
BMI (kg/m2)30.5 ± 4.930.5 ± 6.4
Age at onset of diabetes (years)48.4 ± 9.748.4 ± 9.7
Diabetes duration (years)10.2 ± 7.010.6 ± 6.9
Type of previous treatment
    OAD only815 (71)826 (71)
    Insulin only259 (23)259 (22)
Duration of insulin treatment (years)*7.1 ± 6.76.8 ± 7.3
Duration of OAD treatment (years)7.4 ± 5.48.0 ± 5.2
HbA1c level (%)
    Baseline8.8 ± 1.18.7 ± 1.1
    End point7.8 ± 1.37.7 ± 1.2
Fasting plasma glucose level (mg/dl [mmol/l])
    Baseline199 ± 2 [11 ± 0.1]199 ± 2 [11 ± 0.1]
    End point155 ± 2 [8 ± 0.1]161 ± 2 [9 ± 0.0]
  • Data are means ± SD or n (%).

  • *

    * Only patients in study 3006 (100%) and study 3002 (25%) were on insulin prior to study initiation.

  • P = 0.0233 for the insulin glargine versus NPH insulin group at end point. OAD, oral antidiabetic agent.